Study to Evaluate the Pharmacokinetic Characteristics, Safety, Tolerability, and Preliminary Efficacy of 9MW1911 in Patients With Chronic Obstructive Pulmonary Disease (COPD).

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

July 6, 2023

Primary Completion Date

September 30, 2025

Study Completion Date

September 30, 2025

Conditions
Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Interventions
DRUG

9MW1911

Participants will receive IV 9MW1911 every 4 weeks.

DRUG

Placebo

Participants will receive IV placebo every 4 weeks.

Trial Locations (22)

Unknown

Baogang Hospital (No 3 Hospital Affiliated to Medical College of Inner Mongolia), Baotou

China-Japan Friendship Hospital, Beijing

Peking University Shougang Hospital, Beijing

The First Hospital of Changsha, Changsha

The second xiangya hospital of central south university, Changsha

Chengdu Fifth People's Hospital, Chengdu

Chongqing Red Cross Hospital (People's Hospital of Jiangbei District), Chongqing

Fu Yang People's Hospital, Fuyang

The First Affiliated Hospital of Guangzhou Medical University, Guangzhou

The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou

The Second Hospital, University of South China, Hengyang

The Third People's Hospital of Huizhou, Huizhou

Jiangmen Central Hospital, Jiangmen

Liaocheng People's Hospital, Liaocheng

The First Affiliated Hospital of Nanchang University, Nanchang

Pingxiang People's Hospital, Pingxiang

The First Affiliated Hospital of Qiqihar Medical University, Qiqihar

Tongji Hospital of Tongji University, Shanghai

Shengjing Hospital of China Medical University, Shenyang

Suzhou Municipal Hospital, Suzhou

The First Hospital of Shanxi Medical University, Taiyuan

Taizhou Hospital of Zhejiang Province, Taizhou

All Listed Sponsors
lead

Mabwell (Shanghai) Bioscience Co., Ltd.

INDUSTRY